Literature DB >> 17329328

Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.

Daniel M Held1, Jay D Kissel, Sarah J Thacker, Daniel Michalowski, Dayal Saran, Jianfei Ji, Richard W Hardy, John J Rossi, Donald H Burke.   

Abstract

Reverse transcriptase (RT) remains a primary target in therapies directed at human immunodeficiency virus type 1 (HIV-1). RNA aptamers that bind RT from HIV-1 subtype B have been shown to protect human cells from infection and to reduce viral infectivity, but little is known about the sensitivity of the inhibition to amino sequence variations of the RT target. Therefore, we assembled a panel of 10 recombinant RTs from phylogenetically diverse lentiviral isolates (including strains of HIV-1, simian immunodeficiency virus SIVcpz, and HIV-2). After validating the panel by measuring enzymatic activities and inhibition by small-molecule drugs, dose-response curves for each enzyme were established for four pseudoknot RNA aptamers representing two structural subfamilies. All four aptamers potently inhibited RTs from multiple HIV-1 subtypes. For aptamers carrying family 1 pseudoknots, natural resistance was essentially all-or-none and correlated with the identity of the amino acid at position 277. In contrast, natural resistance to aptamers carrying the family 2 pseudoknots was much more heterogeneous, both in degree (gradation of 50% inhibitory concentrations) and in distribution across clades. Site-directed and subunit-specific mutagenesis identified a common R/K polymorphism within the p66 subunit as a primary determinant of resistance to family 1, but not family 2, pseudoknot aptamers. RNA structural diversity therefore translates into a nonoverlapping spectrum of mutations that confer resistance, likely due to differences in atomic-level contacts with RT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17329328      PMCID: PMC1900219          DOI: 10.1128/JVI.01923-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

Review 1.  Current status of antiretroviral therapy.

Authors:  Zelalem Temesgen; David Warnke; Mary J Kasten
Journal:  Expert Opin Pharmacother       Date:  2006-08       Impact factor: 3.889

2.  Chimpanzee reservoirs of pandemic and nonpandemic HIV-1.

Authors:  Brandon F Keele; Fran Van Heuverswyn; Yingying Li; Elizabeth Bailes; Jun Takehisa; Mario L Santiago; Frederic Bibollet-Ruche; Yalu Chen; Louise V Wain; Florian Liegeois; Severin Loul; Eitel Mpoudi Ngole; Yanga Bienvenue; Eric Delaporte; John F Y Brookfield; Paul M Sharp; George M Shaw; Martine Peeters; Beatrice H Hahn
Journal:  Science       Date:  2006-05-25       Impact factor: 47.728

3.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.

Authors:  J D Thompson; D G Higgins; T J Gibson
Journal:  Nucleic Acids Res       Date:  1994-11-11       Impact factor: 16.971

4.  Catalytic properties of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2.

Authors:  A Hizi; R Tal; M Shaharabany; S Loya
Journal:  J Biol Chem       Date:  1991-04-05       Impact factor: 5.157

5.  Gene transfer in humans using a conditionally replicating lentiviral vector.

Authors:  Bruce L Levine; Laurent M Humeau; Jean Boyer; Rob-Roy MacGregor; Tessio Rebello; Xiaobin Lu; Gwendolyn K Binder; Vladimir Slepushkin; Franck Lemiale; John R Mascola; Frederic D Bushman; Boro Dropulic; Carl H June
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-07       Impact factor: 11.205

6.  pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.

Authors:  J J Eron; Y K Chow; A M Caliendo; J Videler; K M Devore; T P Cooley; H A Liebman; J C Kaplan; M S Hirsch; R T D'Aquila
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

7.  Reverse transcriptase of human immunodeficiency virus can use either human tRNA(3Lys) or Escherichia coli tRNA(2Gln) as a primer in an in vitro primer-utilization assay.

Authors:  L A Kohlstaedt; T A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

8.  RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase.

Authors:  C Tuerk; S MacDougal; L Gold
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

9.  Reduced rate of disease development after HIV-2 infection as compared to HIV-1.

Authors:  R Marlink; P Kanki; I Thior; K Travers; G Eisen; T Siby; I Traore; C C Hsieh; M C Dia; E H Gueye
Journal:  Science       Date:  1994-09-09       Impact factor: 47.728

10.  Single-stranded DNA aptamer RT1t49 inhibits RT polymerase and RNase H functions of HIV type 1, HIV type 2, and SIVCPZ RTs.

Authors:  Jay D Kissel; Daniel M Held; Richard W Hardy; Donald H Burke
Journal:  AIDS Res Hum Retroviruses       Date:  2007-05       Impact factor: 2.205

View more
  20 in total

Review 1.  Novel cell and gene therapies for HIV.

Authors:  James A Hoxie; Carl H June
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

2.  Further characterization of the target of a potential aptamer biomarker for pancreatic cancer: cyclophilin B and its posttranslational modifications.

Authors:  Partha Ray; Bruce A Sullenger; Rebekah R White
Journal:  Nucleic Acid Ther       Date:  2013-10-23       Impact factor: 5.486

3.  Robust suppression of HIV replication by intracellularly expressed reverse transcriptase aptamers is independent of ribozyme processing.

Authors:  Margaret J Lange; Tarun K Sharma; Angela S Whatley; Linda A Landon; Michael A Tempesta; Marc C Johnson; Donald H Burke
Journal:  Mol Ther       Date:  2012-09-04       Impact factor: 11.454

4.  Insight into HIV-1 reverse transcriptase-aptamer interaction from molecular dynamics simulations.

Authors:  Niran Aeksiri; Napat Songtawee; M Paul Gleeson; Supa Hannongbua; Kiattawee Choowongkomon
Journal:  J Mol Model       Date:  2014-07-30       Impact factor: 1.810

5.  Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C.

Authors:  Hong-Tao Xu; Yudong Quan; Eugene Asahchop; Maureen Oliveira; Daniella Moisi; Mark A Wainberg
Journal:  Retrovirology       Date:  2010-10-07       Impact factor: 4.602

6.  Broad-spectrum aptamer inhibitors of HIV reverse transcriptase closely mimic natural substrates.

Authors:  Mark A Ditzler; Debojit Bose; Nikolozi Shkriabai; Bruno Marchand; Stefan G Sarafianos; Mamuka Kvaratskhelia; Donald H Burke
Journal:  Nucleic Acids Res       Date:  2011-07-03       Impact factor: 16.971

7.  Novel bimodular DNA aptamers with guanosine quadruplexes inhibit phylogenetically diverse HIV-1 reverse transcriptases.

Authors:  Daniel Michalowski; Rebecca Chitima-Matsiga; Daniel M Held; Donald H Burke
Journal:  Nucleic Acids Res       Date:  2008-11-07       Impact factor: 16.971

8.  Fluorescence competition assay measurements of free energy changes for RNA pseudoknots.

Authors:  Biao Liu; Neelaabh Shankar; Douglas H Turner
Journal:  Biochemistry       Date:  2010-01-26       Impact factor: 3.162

9.  High-throughput sequence analysis reveals structural diversity and improved potency among RNA inhibitors of HIV reverse transcriptase.

Authors:  Mark A Ditzler; Margaret J Lange; Debojit Bose; Christopher A Bottoms; Katherine F Virkler; Andrew W Sawyer; Angela S Whatley; William Spollen; Scott A Givan; Donald H Burke
Journal:  Nucleic Acids Res       Date:  2012-12-14       Impact factor: 16.971

10.  Potent Inhibition of HIV-1 Reverse Transcriptase and Replication by Nonpseudoknot, "UCAA-motif" RNA Aptamers.

Authors:  Angela S Whatley; Mark A Ditzler; Margaret J Lange; Elisa Biondi; Andrew W Sawyer; Jonathan L Chang; Joshua D Franken; Donald H Burke
Journal:  Mol Ther Nucleic Acids       Date:  2013-02-05       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.